EUCTR2006-003629-98-FI进行中（未招募）不适用
A 54-week, randomized, open-label, multicenter study to assess the long-term safety and tolerability of the combination of aliskiren 300 mg/ amlodipine 10 mg in patients with essential hypertension
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Outpatients 18 years of age and older.
- •2. Male or female patients are eligible.
- •3. For newly diagnosed/untreated patients with essential hypertension defined as
- •DBP > 90 and < 110 mmHg at Visit 1 and Visit 4.
- •4. For previously treated patients with essential hypertension defined as DBP = 90
- •and < 110 mmHg after 2 to 4 weeks of washout (Visits 3 or 4).
- •5. Patients who are eligible and able to participate in the study, and who consent to
- •do so after the purpose and nature of the investigation has been clearly
- •explained to them (written informed consent).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •For full list, please refer to Protocol
- •1. Previously treated in an aliskiren study that contained the treatment group of the
- •combination of aliskiren and amlodipine and had been randomized or enrolled
- •into the active drug treatment period of that study.
- •2. Severe hypertension (msDBP >110 mmHg and/or msSBP > 180 mmHg)
- •3. Pregnant or nursing (lactating) women, where pregnancy is defined as a state of
- •a female after conception and until the termination of gestation, confirmed by a
- •positive hCG laboratory test (> 5 mIU/ml)
- •4. Women of child-bearing potential (WOCBP), defined as all women physiologically
- •capable of becoming pregnant, including women whose career, lifestyle, or sexual
- •orientation precludes intercourse with a male partner and women whose
- •partners have been sterilized by vasectomy or other means, UNLESS they meet
- •the following definition of post-menopausal: 12 months of natural (spontaneous)
- •amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels > 40
- •mIU/ml or 6 weeks post surgical blilateral oophorectomy with or without
- •hysterectomy OR are using one or more of the following acceptable methods of
- •contraception such as surgical sterilization (e.g., bilateral tubal ligation) or
- •hormonal contraception (implantable, patch, oral). Reliable contraception should
- •be maintained throughout the study and for 7 days after study medication
- •discontinuation.
- •5. History or evidence of a secondary form of hypertension
- •6. Any history of hypertensive encephalopathy or cerebrovascular accident, or
- •history within 12 months from visit 1 for transient ischemic attack (TIA),
- •myocardial infarction, coronary bypass surgery, or any percutaneous coronary
- •intervention (PCI).
- •7. Previous or current diagnosis of heart failure (NYHA Class III-IV).
- •8. Serum potassium > 5.3 mEq/L (mmol/L) at Visit 1.
- •9. Patients with Type 1 or Type 2 diabetes mellitus who are not well controlled
- •based on the investigator's clinical judgment. Patients with diabetes mellitus
- •enrolled in this study should be well controlled. It is recommended that patients
- •currently being treated for diabetes mellitus be on a stable dose of antidiabetic
- •medication for at least 4 weeks prior Visit 1.
- •10. Current angina pectoris requiring pharmacological therapy except for nitrates.
研究者
相似试验
进行中（未招募）
不适用
A 54-week, randomized, open-label, multicenter study to assess the long-term safety and tolerability of the combination of aliskiren 300 mg/ amlodipine 10 mg in patients with essential hypertensioHypertensionEUCTR2006-003629-98-DEovartis Pharma Services AG500
进行中（未招募）
不适用
A 54-week, randomized, open-label, multicenter study to assess the long-term safety and tolerability of the combination of aliskiren 300 mg/ amlodipine 10 mg in patients with essential hypertensioHypertensionEUCTR2006-003629-98-BEovartis Pharma AG500
进行中（未招募）
不适用
Evaluation of evolution of renal function in maintenance liver transplant recipients receiving either RAD001 (everolimus) plus reduced TAC or RAD001 (everolimus) plus MMFliver transplantationMedDRA version: 18.0Level: LLTClassification code 10050434Term: Prophylaxis against liver transplant rejectionSystem Organ Class: 100000004865EUCTR2015-000590-12-DEovartis Pharma GmbH
招募中
3 期
A Randomised Controlled Trial of the efficacy and safety of an Inhaled Corticosteroid and Long Acting Beta Agonist maintenance and/or reliever therapy versus standard maintenance with separate reliever therapy in children with mild, moderate and severe asthma.AsthmaRespiratory - AsthmaACTRN12622001217796Medical Research Institute of New Zealand400
尚未招募
3 期
A Randomised Controlled Trial of the efficacy and safety of an Inhaled Corticosteroid and Long Acting Beta Agonist as maintenance and reliever therapy versus as prescribed maintenance with salbutamol as reliever therapy in children with moderate and severe asthma.Respiratory - AsthmaAsthmaACTRN12623001339640The University of Auckland376